These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32853045)

  • 1. Dengue virus 4: the 'black sheep' of the family?
    Lazo L
    Expert Rev Vaccines; 2020 Sep; 19(9):807-815. PubMed ID: 32853045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
    Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
    Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
    Thoresen D; Matsuda K; Urakami A; Ngwe Tun MM; Nomura T; Moi ML; Watanabe Y; Ishikawa M; Hau TTT; Yamamoto H; Suzaki Y; Ami Y; Smith JF; Matano T; Morita K; Akahata W
    J Virol; 2024 May; 98(5):e0023924. PubMed ID: 38647327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.
    Gromowski GD; Henein S; Kannadka CB; Barvir DA; Thomas SJ; de Silva AM; Jarman RG
    Vaccine; 2018 Apr; 36(18):2403-2410. PubMed ID: 29602701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
    Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
    Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
    Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
    Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice.
    Zheng X; Chen H; Wang R; Fan D; Feng K; Gao N; An J
    Front Cell Infect Microbiol; 2017; 7():175. PubMed ID: 28553618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates.
    Strouts FR; Popper SJ; Partidos CD; Stinchcomb DT; Osorio JE; Relman DA
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004731. PubMed ID: 27214236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients.
    Yamanaka A; Moi ML; Takasaki T; Kurane I; Konishi E
    J Gen Virol; 2017 Feb; 98(2):166-172. PubMed ID: 27911254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
    Vigne C; Dupuy M; Richetin A; Guy B; Jackson N; Bonaparte M; Hu B; Saville M; Chansinghakul D; Noriega F; Plennevaux E
    Hum Vaccin Immunother; 2017 Sep; 13(9):2004-2016. PubMed ID: 28598256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
    Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
    Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
    Galula JU; Salem GM; Chang GJ; Chao DY
    Hum Vaccin Immunother; 2019; 15(10):2328-2336. PubMed ID: 31314657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.